PTO/SB/08A (10-96
Approved to/use through 10/31/99. OMB 0651-0031
Patenhand Trademark Office: U.S. DEPARTMENT OF COMMERCE

_1	_
7	_

3	49A/PTO		plete if Known	
INFORMA STATEM (use as	ATION DISCLOSURE ENT BY APPLICANT many sheets as necessary)	Application Number	09/699,003	
& TPABE	•	Filing Date	October 26, 2000	
ì		First Named Inventor	M. Rigdon Lentz	_
		Group Art Unit	3762	
1				
Sheet 1 of		Examiner Name	P. Blanco	

	U.S. PATENT DOCUMENTS								
Examiner Initials*		US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
_		Number Kind Code ² (if known)							
CAR.		5,980,887	Isner, et al.	11-09-1999					
(X)5		6,017,527	Maraskovsky, et al.	01-25-2000	RECEIVED				
					OCT 1 4 2003				
					TECHNOLOGY CENTER H370				
		 - 		 	·				

				F	DREIGN PATENT DOCUMEN	ITS		
Examiner Cite Initials* No.1		Foreign Patent Docu	ment	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1	
	•	Office.3	Number*	Kind Code ⁵ (if known)			Tiguros Appear	
		PCT	WO 91/09967		Celitech Ltd.	07-11-1991		1
out		PCT	WO 01/37873		Lentz	05-31-2001		
		 						
								
		ــــــــــــــــــــــــــــــــــــــ						

Examine		Date Considered	0 - 011	
Signature	SOUND NOW N		2-2-()4	
				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

1	Please	tvoe	A	olus	aian	(+)	inside	this	box -	
•		.,,,,,	•		œw.	177	4.00	000	~~~	•

		PTO	SB/08A	(10-9)
Approved for	use through 1	10/31/99. (DMB 0651	-0031
Petent and Trademark Office:	U.S. DEPAR	RTMENT C	F COMM	ERCI

1	

Under the Pa	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number							
	Substitute for	form 1449.	A/PTO	Co	emplete if Known]		
W 0 8 50	[®] INFOR	MATIO	N DISCLOSURE	Application Number	109/699,003 RECEIVED	þ		
) }	STATE	MENT	BY APPLICANT		OCT 1 4 2003			
T& TRABE	(use	as many si	N DISCLOSURE BY APPLICANT neets as necessary)					
		-	••	Filing Date	October 26, 2000 HOLOGY CENTER F	3700		
1				First Named Inventor	M. Rigdon Lentz			
				Group Art Unit	3762			
				Examiner Name	P. Bianco	•		
Sheet	2	of	3	Attorney Docket Number	LEN 101 CIP CON			

		OTHER ART NON PATENT LITERATURE DOCUMENTS	-
Examiner's Cite Initials* No.1		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
RMS		ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," Cancer Res. 51: 5602-5607 (1991).	
7		AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2:8 resolution," Science 233: 747-751 (1986).	
		CLACKSON, et al., "Making of antibody fragments using phage display libraries," Nature 352: 624-688 (1991).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991)	
		DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," J. Clin. Invest 89: 1690-1693 (1992).	
		ELSASSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993).	
		EY, et al., "Isolation of pure IgG ₁ , IgG _{2a} , and IgG _{2b} immunoglobins from mouse serum using protein A- Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	
		KABAT, et al., eds., <u>Sequences of Proteins of Immunological Interest</u> , 4 th ed., U.S Dept. Health & Human Services: Bethesda, MD (1987).	_
		KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Puril</i> . 11: 150-157 (1993).	
and		LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997).	

• •	 	
Examiners		
	Date Considered	7 2 41
Signature		L-/-04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) Inside this box →	+	

		PT	O/SB/08A	(10-9
Approved for a	use through	10/31/99.	OMB 065	1-003
Patent and Trademark Office:	U.S. DEPA	RTMENT	OF COMIN	IERCI

1		ute for form 1	449A/P	го			Complete If	Known	RECEIN	/=-
CI OBI		ORMAT ATEMEN				Application Number		09/699,003	OCT 14	
Y & TEAR						·		_	FOUNDLOOK OF	
		(use as mar	ny sheet	s as necesse	ary)				ECHNOLOGY CEN	HEKK
						Filing Date		October 26, 2		
					'	First Named Inventor		M. Rigdon Le	intz	
						Group Art Unit		3762		
A						Examiner Name		P. Blanco		
eet	;	3 of	i_	3		Attorney Docket Number		LEN 101 CIP	CON	
			· · · · · · · · · · · · · · · · · · ·	OTHE	R ART - N	ON PATENT LITERATURE	DOCUMENTS			
aminers	Cite]	tr	iclude name of	f the author (in CAPITAL LETTERS), title of t	he article (when appro	priate), title of th	e	T
itials*	No.1		iter	n (book, maga	zine, journal, p	, serial, symposium, catalog, etc publisher, city and/or country who	.), date, page(s), volun ere published	ne-issue number	(8),	
N/b		PANKA, et digoxin ant	al., "Va ibodies	riable region," <i>Proc. Na</i>	on framew ti. Acad. S	vork differences result in Sci. USA 85: 3080-3084 (decreased or inc (1988).	reased affinit	y of variant anti-	
1		RUDIKOFF 1983 (1982	, et al. 2).	"Single an	nino acid s	substitution altering antig	en-binding specif	icity," <i>Immui</i>	nology 79: 1979-	
J		SELINSKY persistence	& HOV	VELL, "Sok o," <i>Cell. Im</i> r	uble tumo nunol. 200	r necrosis factor recepto 0: 81-87 (2000).	r type I enhances	tumor devel	opment and	
Pur		SELINSKY University,	, "Disse Fort Co	ertation: The ollins, Color	e role of s rado (1999	coluble tumor necrosis fac 9).	ctor type I in tumo	or survival," (Colorado State	
				··· -			 			
										
		<u>.</u>								
								·		
					•					
					<u> </u>					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Examiner's

Signature

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.